Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma.

Next Previous
Trial Profile

Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEDI 6469 (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use

Most Recent Events

  • 31 Mar 2014 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 12 Oct 2012 Actual initiation date (Oct 2012) added as reported by ClinicalTrials.gov.
  • 12 Oct 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top